NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
-7.32%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.93B
AUM Growth
+$1.93B
(-14%)
Cap. Flow
-$89.8M
Cap. Flow
% of AUM
-4.64%
Top 10 Holdings %
Top 10 Hldgs %
70.83%
Holding
57
New
3
Increased
7
Reduced
11
Closed
8
Top Buys
| 1 |
Boston Scientific
BSX
|
$150M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$16M |
| 3 |
Pharvaris
PHVS
|
$5.46M |
| 4 |
Amicus Therapeutics
FOLD
|
$5.37M |
| 5 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$4.57M |
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
$53M |
| 2 |
Inogen
INGN
|
$43.1M |
| 3 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$33.7M |
| 4 |
INZY
Inozyme Pharma
INZY
|
$31.8M |
| 5 |
Protagonist Therapeutics
PTGX
|
$26.9M |
Sector Composition
| 1 | Healthcare | 57.28% |
| 2 | Financials | 8.56% |
| 3 | Technology | 7.59% |
| 4 | Consumer Discretionary | 1.65% |
| 5 | Communication Services | 1.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
51
DELISTED
Inozyme Pharma
INZY
| – | – |
-1,867,706
| Closed | -$31.8M |
|
52
Legend Biotech
LEGN
$6.41B
| – | – |
-279,676
| Closed | -$11.5M |
|
|
53
Protagonist Therapeutics
PTGX
$3.67B
| – | – |
-600,010
| Closed | -$26.9M |
|
|
BNT
54
Brookfield Wealth Solutions Ltd.
BNT
$18.7B
| – | – |
-21,179
| Closed | -$1.1M |
|
|
EAR
55
DELISTED
Eargo, Inc. Common Stock
EAR
| – | – |
-237,071
| Closed | -$9.46M |
|
|
XENT
56
DELISTED
Intersect ENT, Inc
XENT
| – | – |
-508,922
| Closed | -$8.7M |
|
|
BHVN
57
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-53,300
| Closed | -$5.17M |
|